SPARC and methods of use thereof
First Claim
1. A method of treating a cancer of the breast, lung, colon, prostate, or head and neck in a mammal with a chemotherapeutic regimen or other anticancer regimen comprising paclitaxel, said method comprising:
- (a) isolating a biological sample of cancerous cells from the mammal, (b) detecting the expression of SPARC protein in the biological sample, (c) quantifying the amount of SPARC protein in the biological sample to determine whether the biological sample is positive for SPARC expression, (d) detecting the expression of Her2 protein in the biological sample, (e) quantifying the amount of Her2 protein in the biological sample to determine if the biological sample is positive for Her2 expression, and (f) if the biological sample is positive for SPARC expression and positive for Her2 expression, administering a therapeutically effective amount of the chemotherapeutic regimen or other anticancer regimen to the mammal.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
23 Citations
7 Claims
-
1. A method of treating a cancer of the breast, lung, colon, prostate, or head and neck in a mammal with a chemotherapeutic regimen or other anticancer regimen comprising paclitaxel, said method comprising:
- (a) isolating a biological sample of cancerous cells from the mammal, (b) detecting the expression of SPARC protein in the biological sample, (c) quantifying the amount of SPARC protein in the biological sample to determine whether the biological sample is positive for SPARC expression, (d) detecting the expression of Her2 protein in the biological sample, (e) quantifying the amount of Her2 protein in the biological sample to determine if the biological sample is positive for Her2 expression, and (f) if the biological sample is positive for SPARC expression and positive for Her2 expression, administering a therapeutically effective amount of the chemotherapeutic regimen or other anticancer regimen to the mammal.
- View Dependent Claims (2, 3, 4, 5, 6, 7)
Specification